Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative

Sonia Prabhakaran1, Dhiviya Thirumal2, Jolius Gimbun3,4, Balu Ranganathan5

1Department of Biotechnology, Sri Venkateswara College of Engineering, Pennalur, Kancheepuram District, Sriperambudur - 602117, Tamil Nadu, India
2Department of Medicine, Karpaga Vinayaga Institute of Medical Sciences and Research Center, Chinna Kolambakkam, Palayanoor PO, Kanchipuram Dist, Madurantagam - 603308, Tamil Nadu, India
3Faculty of Chemical and Natural Resources Engineering, University Malaysia Pahang, Gambang Campus, Gambang - 26300, Malaysia
4Centre of Excellence for Advanced Research in Fluid Flow (CARIFF), University Malaysia Pahang, Gambang Campus, Gambang - 26300, Malaysia
5Palms Connect Sdn Bhd, Shah Alam - 40460, Selangor Darul Ehsan, Malaysia

Abstract

Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems (NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug hence the potential of technology development start-ups can neither be underwritten nor underestimated even when there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company.

Keywords: Antineoplastic Drug, Breast Cancer, Clinical Trials, Metformin, Start-Up Company

1. Introduction

Metformin is the oral antihyperglycaemic drug of choice for type 2 diabetes mellitus treatment. This drug is unique from other oral antihyperglycaemic agents in the sense that this drug of choice not only subdues hepatic glucose production, reduces the intestinal glucose absorption and to a further extent improves insulin sensitivity. This drug proves further uniqueness in not causing hyperinsulinemia. In-vitro and in-vivo studies suggest for a direct connectivity between diabetes and oncological manifestations. This review works and moves in the direction to depict metformin being an oral antihyperglycaemic drug at some point of time may act also as an anticancer drug wherein this combinatorial property is not exhibited by other antihyperglycaemic drugs. In the scope of this article, convergence revolution initiates the integration (rather than as collaboration) of chemical engineering, biotechnology, medicine with the aid of multinational corporation, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company.
business incubator, philanthropic foundation and startup company with the best ability to forge a new innovative initiative path for the technology development for the cure of breast cancer. This is very much depicted by the authors of this article who are chemical engineers, bioengineers, design engineers, biotechnologists, design engineer medical practitioners (both specialized and budding), philanthropists, technology developers and big data analysts. More integration from regulators, onco-psychologists and federal funders would further accelerate for the cure of breast cancer with the classical example of cancer moonshot initiative.

2. History

Medieval Europe used *Galega officinalis* Lin possessing white, blue or purple flowers as an extract to be used as an herbal medicine. Chemical analysis revealed guanidine and associated compounds were found to be abundant in the extracts of *Galega officinalis* Lin dating back to mid-1800s. The plant is also called as goat’s rue, French lilac (Figure 1), Spanish sanfoin and false indigo.

In 1918, belonging to a class of drugs that has been part of the human apothecary for 500 years, guanidine...
was reportedly reduced blood glucose levels in animal models. The chemical itself was first reported in 1922 by the Dublin chemists Emil Werner and James Bell.

Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clinical tests, proved useful to treat influenza when it sometimes lowered blood glucose.

First report on the clinical use of metformin for the treatment of diabetes was in 1957 by the French physician Jean Sterne. A French company called Aron Laboratories, situated in Suresnes, Paris, France granted permission Jean Sterne to carry out his clinical trials experiments. Sterne selected dimethylbiguanide (metformin) for clinical development and proposed the name ‘Glucophage’ (glucose eater).

Jean Sterne's scientific temperament, administrative mettle with sharp enquiring mind facilitated the pragmatic prodigious experimentation appended by his perceptive clinical sixth sense transformed the blood-glucose diminutive potential of metformin into a therapeutic commercial success culminating him into a visionary.

3. United States Scenario

After several decades only United States of America was able to use metformin after FDA approved metformin in 1994, Bristol-Myers Squibb has applied (Application number: 020357/S010) for metformin. An important clinical trials of metformin was carried out in 1995 in USA immediately after the FDA approval.

Currently it is estimated that approximately, 37,000 metric tons of metformin is manufactured and mostly in FDA approved pharmaceutical companies in India.

4. Clinico Pharmacology

4.1 Chemical Synthesis

Synthesis of metformin dates back to 1920s (Figure 2), when metformin was synthesized using a single step process involving the reaction of dimethylamine hydrochloride and 2-cyanoguanidine (dicyanidiamide) upon heating at increased temperature levels. Equimolar quantities of dimethylamine and 2-cyanoguanidine are made into a solution using toluene as the solvent, with gradual addition equimolar amount of hydrogen chloride the solution starts boiling and upon cooling, precipitation occurs. The precipitate formed is N, N-dimethylimidodicarbonimidic diamide hydrochloride with a 96% yield which is Metformin hydrochloride. Metformin hydrochloride (IUPAC: N, N-dimethylimidodicarbonimidic diamide hydrochloride) is the Active Pharmaceutical Ingredient (API) of the finished product of the oral antihyperglycemic drug used for the treatment and management of type 2-diabetes.

5. Estimation of Metformin in Biological Fluids

Sensitive and specific methods for analysis of biguanides in biological fluids are essential to an evaluation of their safety and efficacy. Metformin can be determined in biological fluids by various methods. Early assays were based on spectrophotometry which has a low specificity and sensitivity.

Mass spectrometry has been developed but the equipment required is not generally available in a routine analytical laboratory. High performance liquid chromatography is now considered as the method of choice for the assay of metformin because of its simplicity, rapidity, high specificity, reproducibility and sensitivity. Quite recently the plasma concentration of metformin is being determined using Liquid chromatography tandem mass spectroscopy (LC–MS/MS System). Other methods for estimation of metformin from blood plasma includes Ion pair liquid chromatography and HPLC with spectrophotometric detection.

6. Pharmacological Actions

Metformin is found to affect multiple key processes related to cell growth, proliferation, and survival. Metformin which is a panacea drug has the potential to treat myriads of diseases which are type 2 diabetes mellitus, cardiovascular risks, life extension for pancreatic cancer patients, polycystic ovarian syndrome, oncogenic tumors and now on the clinical trials for breast cancer.
6.1 Diabetes Mellitus

For type 2 diabetes for more than half a century, the drug of choice is metformin, for it is an orally administered drug in the form of tablets. The well-known trade name is called as Glucophage™. The implicating factors associated with the manifestation of the type 2 diabetes are well counteracted by the panacea drug Metformin. This drug acts with maximum efficacy on the levels of glucose and lipids in blood. To be more specific with a scientific representation, the protective effects make this drug of choice to be more efficient in terms of the adverse metabolic side effects of the other drugs which results often in obesity. Under physiological conditions, if cells become insulin-resistant, they no longer respond to insulin release by absorbing glucose. More glucose stays in the bloodstream, a condition known as hyperglycemia. Metformin improves insulin sensitivity in the peripheral tissues and thereby controls excessive glucose production. Metformin has been prescribed to overcome obesity15–18.

6.2 Polycystic Ovarian Syndrome (PCOS)

Metformin treats PCOS, major physiological manifestation of this syndrome being obesity and infertility. PCOS19,20 is linked with higher levels of circulating insulin, which is characteristic in type 2 diabetes. Several endocrine and metabolic physiological abnormalities like insulin resistance and systolic blood pressure have been countermanded by the oral administration of metformin. Insulin resistance occurs most often in people who have a family history of obesity and women who have PCOS. Sedentary lifestyle also contributes to insulin resistance. People with insulin resistance often gain weight. High insulin levels can increase hunger, people with high insulin levels gain weight. Since metformin is a drug which lowers insulin results in an improved weight loss. Metformin along with a structured lifestyle intervention21–23 improves insulin sensitivity through increasing muscle glucose uptake and use. Obstetrics and gynecological conditions like irregular menstrual cycles and delayed pregnancy has been reversed at the doses of 500 mg to 850 mg of metformin thrice a day.

6.3 Cardio Vascular Risks

Metformin treats cardiovascular risks in Diabetic as well as non-diabetic individuals. Several cardiovascular associated diseases like hypertension and hypofibrinolysis could be treated using metformin24. Metabolic abnormalities consociated with cardiovascular diseases in particular visceral obesity is also being tackled by metformin. These associated factors conduce the enhanced cardiovascular risks associated with patients suffering from type 2 diabetes. Thereby, regular medications with metformin reduce cardiovascular risk.

6.4 Breast Cancer

In the in-vitro breast cancer cell lines experimentation, hormone receptor subtypes of breast cancer, AMPK stimulation25–27 by metformin leads to total cell growth inhibition in Estrogen Receptor (ER)-positive in-vitro cell lines. In terms of ER-negative cell lines partial inhibition is observed. The drug’s effects on these processes stem from both metabolic and intracellular-signaling activity. The action of metformin on cancer cell proliferation is associated with AMPK activation, reduced Mammalian Target of Rapamycin (mTOR) signaling and protein synthesis, as well as a variety of other responses including decreased epidermal growth factor receptor (EGFR), Src, and mitogen-activated protein kinase (MAPK) activation, decreased expression of cyclins, and increased expression of p2728,29. Metformin has been found to induce apoptosis in certain cell lines derived from endometrial cancers, glioma, and triple negative breast tumors. Therefore from these mechanisms it is quite evident that metformin prevents cancer30,31. The panacea drug Metformin is still under clinical trials for breast cancer.

6.5 Global Manufacturing Scenario

Global population of has now reached 7.5 billion of which 8.5% are living with diabetes approximately 420 million are in need of antihyperglycemic drug. As per FDA’s Drug Master File (DMF) filings there are 18 leading global metformin producers. The average plant capacity of each producer would be about 3800 tons per year. Currently it is estimated that approximately, 37,000
metric tons of metformin is manufactured annually and mostly in FDA approved companies in India.

The generic Metformin is manufactured by 129 companies with 258 Brands of Generics of Metformin. Key API global manufacturers are: Bristol-Mayers Squibb, Shouguang Fukang Pharmaceutical, Harman Finochem, Vistin Pharma, Cr Double-Crane, Keyuan Pharmaceutical, Farmhispania Group, Shijiazhuang Polee Pharmaceutical, Merck Sante and Aarti Drugs.

6.6 Mechanism of Action in Anticancer Activity

At the time of working on this report writing, there has not been a substantial scientific evidence of molecular mechanistic pathway of anticancer activity of metformin. Several plausible molecular mechanistic pathway has been reported for metformin’s antineoplastic action on the basis several in vitro studies.

Several proposed mechanisms are:

• Decreased LKB1 thereby a reduction AMPK levels resulting in mTOR activation followed by decreased S6 kinase activation
• Increased expression of REDD1 resulting in diminished mTOR activation followed by decreased S6 kinase activation
• Inhibition of STAT3 facilitating and enhancing apoptosis induction
• Alteration of the expression oncological associated miRNAs namely, miRNA let7A and miRNA-181

Metformin affects cell signaling pathways directly or indirectly at multiple points. For this reason, the drug may be useful against numerous cancer types.

As it has been mentioned, metformin acting directly on cancer cells have been reported where the chemical moiety acts on the mitochondrial respiration resulting in the stimulation of AMP-Activated Protein Kinase (AMPK). This stimulation action cascades to the activation of liver kinase B1 (LKB1). The elemental upstream kinase of AMPK is being, LKB1. For regular maintenance of energy homeostasis in the cellular environment AMPK and LKB1 are the necessary elements for the normal physiological activities.

The other mechanism being an indirect action more on the host cell metabolism where reduced activity of hepatic gluconeogenesis (AMPK mediated) resulting in lowered circulating insulin levels. Involvement of lowered activation of PI3K pathway mediated by insulin/IGF-1 receptor has also been reported.

Mammalian target rapamycin complex 1 (mTORC1) suppression is mainly associated with the anticancer molecular action of metformin. Metabolism, growth and proliferation of cancer cells are the pivotal roles played by the mTOR. It is observed that mTORC1 pathway is inhibited by metformin.

Metformin inhibits Mtor pathway both by dependent and as well as independent of AMP-activated protein kinase activation as suggested by evidences. Tuberculosis sclerosis complex protein 2 (TSC2) is phosphorylated by AMPK, which inhibits Mtorc. This inhibition of Mtor leads to decreased activities of protein synthesis and finally at the macro level, the cell growth. Since AMPK directly phosphorylates Mtor, inhibition of Mtor could be independent on TSC2. Metformin directs the upregulation of AMP-activated protein kinase. This is the key molecule in the regulation of glucose and insulin levels. It also plays a role as an inhibitor of mTOR.

Metformin acts on the hepatic cells whereby decreasing the levels of glucose produced by the hepatic cellular action resulting in the bloodstream levels and also on the cellular uptake of insulin. These molecular actions trigger a cascade of mechanisms at the molecular level leading to the down regulation of the Ras/Raf/MEK/ERK. Also it triggers PI3K/AKT/mTOR signaling pathways. Any one or both of the above mentioned pathways are regularly activated in different types of carcinogenesis.

Autophagy is activated by AMPK directly and indirectly activating ULK1. AMPK also appears to stimulate mitochondrial biogenesis by regulating PGC1α (a mitochondrial stimulator of metformin biogenesis) which in turn promotes gene transcription in mitochondria.

The plausible mechanism pathways hypothized can give the federal funding agencies to give a thinking to approve and fund the technology development in animal models to increase and improve the efficacy of metformin as an antineoplastic drug.

6.7 Controlled Release

A novel drug delivery nanocomposite film based system made of poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (BP) polymers
ANTICANCER ACTION OF METFORMIN

Fig. 4. Anticancer activity of metformin.

embedded with metformin and MCM-41 or MCM-41-APS (APS = Aminopropylsilane) nanoparticles (NPs) was produced. A short burst release was observed by one day (22-24 hours) then a sustained controlled release for 15 days was observed. The film containing 4%MCM-41-APS NPs had the slowest release (45% release after 15 days).43

Co-encapsulation of cisplatin and metformin using Polyglutamic Acid (PGA) was synthesized. A cationic polymeric agent namely Polymeric Metformin (polymet) was used for the treatment of Non-Small Cell Lung Cancer (NSCLC). A cationic liposomes containing of DOTAP44 (2,3-Dioleoyloxy-propyl)-trimethylammonium/Cholesterol/DSPE-PEG-anisamide aminoethyl was used as the stabilizing agent. A synergistic action was observed whereby the tumor growth was suppressed by the mechanism of apoptosis NSCLC H460 tumor-bearing mice.

Table 1: List of clinical trials of metformin for breast cancer therapy

<table>
<thead>
<tr>
<th>ID</th>
<th>Intervention</th>
<th>Phase</th>
<th>Dosage (mg)</th>
<th>Duration (weeks)</th>
<th>Outcome (primary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00909506</td>
<td>Metformin</td>
<td>II</td>
<td>500 mg (once a day)</td>
<td>1-2</td>
<td>Weight loss</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td></td>
<td>Placebo pill (every morning)</td>
<td>3-24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metformin 500 mg (every evening)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Escalation study:</strong></td>
<td></td>
<td>Metformin 500 mg (every morning and evening)</td>
<td>3-24</td>
<td></td>
</tr>
<tr>
<td>NCT01266486</td>
<td>Metformin (Extended release)</td>
<td>II</td>
<td>Extended release Metformin (1500mg once daily)</td>
<td>2-3</td>
<td>Biomarkers: S6K, 4E-BP-1, AMPK</td>
</tr>
<tr>
<td>NCT00897884</td>
<td>Metformin</td>
<td>NA</td>
<td>Metformin (500 mg) Thrice daily</td>
<td>2-3</td>
<td>Cell proliferation reduction</td>
</tr>
</tbody>
</table>
Ionic-gelation method was used for the synthesis of O-carboxymethyl chitosan (O-CMC) nanoparticles embedded with metformin. A therapy for pancreatic cancer was tried upon. Metformin embedded nanoparticles exhibited higher cytotoxicity on pancreatic cancer cell lines (MiaPaCa-2) in comparison with normal cell lines (L929) resulting in targeted delivery showing a prospective aspect of the synthesized nanoparticles.

Hyaluronic acid-Au nanoparticles embedded with metformin were synthesized for a potential therapy for liver cancer. Active targeting principle was exhibited for the apoptosis liver cancer (HepG2 cells). In terms of the dosage lower amount the nanoformulation was sufficient for 50% inhibition (IC50) when compared to the free metformin.

A different technique of electrospinning called emulsion electrospinning was used for the production of nanofiber scaffolds embedded with metformin hydrochloride. The nanocarriers are made of poly (ε-caprolactone) (PCL) and Poly (3-Hydroxybutyric Acid-Co-3-Hydroxyvaleric Acid) (PHBV) organic biocompatible polymers. PCL nanocarriers were compared with PHBV nanocarriers for their controlled drug release efficiency. It has been reported that PCL nanofiber scaffold was able to deliver at a controlled way over a period of time and also with lowest burst release.

Metformin surface modified cellulose nanofibers (Met-Cel-NFs) were successfully prepared by attachment of metformin on the surface of cellulose nanofibers through electrostatic inter-action.

Gels composed of cellulose based nanofibers embedded with metformin were manufactured as a potential anti-metastasis novel nano drug delivery system for the prevention of human melanoma cancer metastasis. Mode of administration of this novel gel is quite easy in the sense Met-Cel-NFs gel could be sterilized easily and injected around or into the tumor.

### 6.8 Clinical Trials

#### 6.8.1 First Clinical Trial

First clinical trials for metformin were carried out in Paris in 1957 for type 2 diabetes. Earlier years, metformin was called as glucophage (‘glucose eater’). Clinical trials were so successful in the way blood glucose with type 2 diabetes was lowered but unaltered in the subjects who were non-diabetic.

A report published in 2005 reported the use of metformin decreased the risk of cancer by 23% Moving forward, in 2012, substantial evidence was obtained with an insight for metformin as an antineoplastic agent (Figure 4).

Progression free survival (PFS), Relapse/Recurrence Free Survival (RFS), and Metastasis-Free Survival (MFS), combined together called as patient overall disease-free survival (OS) should be the major outcome of a clinical trial. FDA has not yet approved the use of metformin as a single chemotherapeutic agent for breast cancer but very much of a possibility in the near future. Insulin entered the commercial market nearly the same time when metformin was in the final stages and phase of clinical trials which really masked the greater panacea drug potential of metformin. Insulin was never tried as a stand-alone generic or even as an adjuvant for any other disease apart from diabetes but for good metformin is in the clinical trials for poly cystic ovary syndrome, anti-ageing, cardio vascular intervention and onco tumorogenesis especially breast cancer. Clinical trials in the direction of diabetic subjects suffering from breast cancer for which medication regimen is quite challenging when compared to non-diabetic subjects with breast cancer, metformin may become a panacea drug as we are getting very prospective clinical trials endpoint results. It is a well-known fact that elevated levels of glycolysis is observed in cancer patients in the scientific terms metabolism, glucose regulation and inflammation influence cancer manifestation outcomes especially breast cancer. Planning a clinical trial using metformin, metformin with a Breast Cancer Drug (BCD), only BCD and insulin with BCD should pave way for better understanding. By including two different categories of clinical trials breast cancer patient volunteers namely breast cancer patients with diabetes and breast cancer patients free of diabetes would provide a very informative insight for the panacea action of metformin for breast cancer.

As of date, there are six clinical trials (NCT00897884, NCT01266486, NCT01650506, NCT00909506, NCT01885013, NCT00659568) that have been completed using metformin as an intervention for breast cancer (Table 1).
Of which three⁵¹–⁵³ of the clinical trials have used metformin as a single intervention of choice. With supporting evidences based on several clinical trials, it is practically evident that metformin is used as a chemotherapeutic agent for tumor growth suppression (NCT01310231⁵⁷, NCT00930579⁵⁸) on breast cancer patients. With the advent of convergence revolution⁵⁹ future of oncological interventions belongs to localized chemotherapy by the use nanocarriers⁶⁰ using biocompatible polymers⁶¹, hence metformin would be for more number of further clinical trials.

7. Conclusion

Principally by scientific evidence metformin molecular mechanistic action is by decreasing the glucose levels produced by the liver, reducing the bloodstream level and cascading by cellular uptake of insulin. In turn, the reduced insulin stimulation results in reduced activation of insulin receptors on cell membranes, triggering a cascade of intracellular molecular effects on various signal pathways. These pathways are often activated in many types of cancer cells. Cancer patient being treated for diabetes dwell with comorbidity ending up in psychological depression and financial ruin. Based on the in-vitro and in-vivo results there are a great potential to prescribe metformin as a combinatorial therapeutic agent. At the translational research level, in vitro and in vivo studies have supported the use of metformin in several cancer types and, along with tumor specimen biomarker studies, have begun to elucidate the molecular mechanisms of metformin's action. The bloom of the French lilac may be realized to blossom and flower in a new direction in the therapy for not only diabetes mellitus but also cardiovascular risks, polycystic ovarian syndrome, oncogenic tumors and of course for the cure of breast cancer.

8. Conflict of Interest

One of the authors, Balu Ranganathan discloses financial interest in Palms Connect Sdn Bhd, Malaysia holds stock options in the company.

9. Authors Contributions:

All the authors conceived the idea on convergence integration. S.P. and D.T worked and designed the figures. S.P and B.R. deliberated the manuscript subject matter and wrote the manuscript. B.R. revised the document upon reviewer comments.

10. References

5. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/nda98/020357s010.cfm


42. Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn. 2011; 121:81–7. PMid:21430609


56. Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma 2008-2013. Available from: https://clinicaltrials.gov/ct2/show/NCT00659568

